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Background: Operative risk scoring algorithms identify patients with severe AS for transcatheter valve implantation
in whom the anticipated operative mortality for conventional surgery would be considered prohibitive. We
compared the three risk scores EuroScore 1 (LES), society of thoracic surgeons’ (STS) score and ACEF
(age-creatinine-ejection fraction score) to the readjusted EuroScore 2 recently presented.
Methods: We reviewed all consecutive patients receiving either isolated conventional aortic valve replacement
(cAVR) or transapical aortic valve implantation (TA-TAVI) in a two-year period (n = 206). 30-days mortality was
considered as primary endpoint.
Results: TA-TAVI was performed in 76 patients, isolated cAVR in 130 patients. Overall mortality was 4.4% (TA-TAVI:
7.9%; cAVR: 2.3%). EuroScore 2 showed a good estimation for the entire population as well as within the subgroups:
4,02 ± 5,36% (TA-TAVI: 6.16 ± 7.14%, cAVR: 2.77 ± 3.42%). Predicted mortalities as assessed by LES were largely
overestimated (TA-TAVI: 27.4 ± 20.9% cAVR: 10.6 ± 10.6%, sensitivity: 0.89, specificity: 0.71). STS predicted mortality
was 6.3 ± 4.4% for TA-TAVI patients as to 3.2 ± 3.1% for cAVR patients (sens.: 0.22, spec.: 0.96) and ACEF predicted a
mortality of 1.16 ± 0.36% for cAVR and 1.58 ± 0.59% for TA-TAVI patients (sens.: 0.78, spec.: 0.89).
Conclusion: The newly refined EuroScore 2 showed a good correlation within the studied population. For the
individual patient, new cut-offs will have to be defined to triage patients for TAVI procedure. A drawback for
complex score systems such as EuroScore and STS is the lack of recalibration to smaller populations as encountered
in even large single centers.
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Calcific Aortic Stenosis (AS) still is the most common
acquired heart valve disease in western countries. [1]
Aortic valve replacement (AVR) has been the gold stand-
ard for the treatment of severe AS for decades, and
the indications for its implementation have been
well defined by the American College of Cardiology /
American Heart Association in 2006 [2] or the 2007
European Guidelines. [3] However, there is growing evi-
dence across western countries that over 30% of patients* Correspondence: agoetzenich@ukaachen.de
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distribution, and reproduction in any mediumwith severe AS are not referred for AVR. Reasons given
for nonoperative management included “old age”, “se-
vere comorbidities” and “patient refusal” [4,5]. Trans-
catheter alternatives to standard AVR have been
developed and successfully deployed in patients in whom
the risk of conventional AVR (cAVR) for severe AS was
considered to be too high. Operative risk scoring algo-
rithms are currently being used to identify and select
patients with severe AS for transcatheter valve implanta-
tions (TAVI) in whom the anticipated operative mortal-
ity for conventional surgery would be considered
prohibitive. However, the accuracy of these risk models
in identifying high-risk patients appropriate for non-
standard valve therapy is not fully validated. TAVI –tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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mended in patients exceeding a logarithmic EuroScore
of 20% according to recent evidence on safety and effi-
cacy of TAVI [6]. LES, although accurate in correlating
predicted and observed mortality in ranges below 5-10%,
[7] has been clearly demonstrated to overestimate
expected mortality by a factor of three [8] in high-risk
candidates for AVR. For this cause, a recalibrated ver-
sion, named EuroScore 2, was recently presented [9] and
first validation studies were published [10].
The STS score system is a very complex model and
difficult to obtain for all routine patients. [11,12] In the
study by Dewey and Herbert [13] which compared the
accuracy of the old LES and the STS in the highest risk
patients, in the latter the observed mortality was much
closer to the expected with an underestimation of 0.8 ra-
ther than overestimation by factor 3. STS risk algorithm,
albeit not perfect, is soundly based on surgical outcome.
It has clearly become the preferred method of risk as-
sessment and evaluation. Although the predictive value
of a score might be of interest, its discriminative power
is of higher importance when it is used to triage
patients.
Recently, the group of Ranucci et al. introduced the
ACEF-score, presenting a simple score including as
few as three different parameters: patient’s age, ejection
fraction and serum creatinine [14]. However, various
factors that also impact mortality but are not incorpo-
rated in either algorithm include liver disease, frailty,
porcelain aorta, neurocognitive dysfunction, and previ-
ous radiation [15].
While the logistic EuroScore (LES) is routinely deter-
mined preoperatively in every patient admitted to our
department, we performed a retrospective analysis of all
consecutive patients admitted for either isolated conven-
tional aortic valve replacement or transapical aortic valve
implantation between January 2008 and December 2009.
We compared the three presented risk scores ACEF,
STS and LES to the recently presented readjusted Euro-
Score 2 as well as further details on hospitalisation and
laboratory parameters.
Methods
Since 2008, the transapical aortic valve implantation
(TA-TAVI) has been performed in our department. We
reviewed all consecutive patients receiving either isolated
conventional av-replacement (cAVR) or TA-TAVI in a
two year period, starting on January 1st 2008 until De-
cember 31st 2009 (n = 206).
Within this period, the decision for either TA-TAVI or
cAVR was mainly based on the LES and made by an
interdisciplinary board of cardiologists and cardiac sur-
geons. It was guided by the recommendations that ac-
companied the CoreValve safety and efficacy trials thatwere later included into the aforementioned recommen-
dations, where among other criteria, a LES cut-off value
of 20% was recommended.
End points
Mortality within 30 days of the procedure was consid-
ered as primary endpoint. Several other clinical para-
meters were evaluated as secondary end points. These
can be summarized as figures on hospitalisation (dur-
ation of operative procedures, time on respirator and
days on ICU) and laboratory parameters (troponin T,
CK-MB, creatinine).
Statistical analysis
All values are given as mean and standard deviation where
appropriate. Statistical analysis was performed using
PASW 18 (IBM Statistics, USA) on an Apple System
(Apple, USA). ANOVA or Student T-tests were performed
where appropriate. Correlation analysis of Euroscore 2
vs. LES was performed by use of the Kendall-Tau-b test.
P-Values are given in exact numbers; a p-value smaller
0.05 was highlighted as a statistically significant outcome.
Boxplots were used to identify individual relationship be-
tween EuroScore 2 and LES, STS or ACEF. Mosaic plots
were used to graphically represent the 3-dimensional con-
tingency tables. Discriminatory power was assessed by
receiver-operation characteristic-curve (ROC-curve) evalu-
ation and the c-index (AUC; area under the ROC-curve).
Cut-off values for STS and LES were derived from current
therapeutic recommendations. The cut-off for the ACEF
score was calculated from the point of maximal specificity
and sensitivity (Youden’s Index). A cut-off value for the
EuroScore 2 is still to be presented. Due to the small num-
ber of patients included in our study, a calibration was
statistically not permitted for the complex EuroScore 2, yet
we decided to present a cut-off based on the Youden’s
Index as well to enhance comparison to the other score
systems. It has to be emphasized that this cut off lacks a
statistical validity.
Research carried out on humans was in compliance
with the Helsinki Declaration. The study was approved
by the local ethics committee and following informed
consent.
Results
Between January 1st 2008 and December 31st 2009, 206
patients were admitted for isolated aortic valve replace-
ment. Of these, TA-TAVI was performed in 76 patients;
isolated cAVR by biological or mechanical valve pros-
thesis was performed in 91 and 39 patients, respectively.
Sex was almost evenly distributed (46.6% females in all
patients) although more females received TA-TAVI
(59.2%; 39.2% for cAVR). Overall mortality was 4.4%,
with 7.9% in the TA-TAVI-group and 2.3% in cAVR
Goetzenich et al. Journal of Cardiothoracic Surgery 2012, 7:89 Page 3 of 7
http://www.cardiothoracicsurgery.org/content/7/1/89patients. Predicted mortalities as assessed by the old lo-
gistic EuroScore were largely overestimated, namely
27.4 ± 20.9% for TA-TAVI patients compared to
10.6 ± 10.6% for cAVR patients. STS predicted mortality
was 6.3 ± 4.4% for TA-TAVI patients as to 3.2 ± 3.1% for
cAVR patients and ACEF predicted a mortality of
1.16 ± .36% for cAVR and 1.58 ± .59% for TA-TAVI
patients. The prediction by EuroScore 2 showed a good
estimation both in the entire population and within the
subgroups: 4,02 ± 5,36% (TA-TAVI: 6.16 ± 7.14%, cAVR:
2.77 ± 3.42%). Further details on both patient collectives
are also shown in Table 1.
As expected, figures on hospitalisation differ substan-
tially between the two operative procedures. The less inva-
sive procedure of TA-TAVI is faster (80 ± 28 min vs.
168 ± 42 min for cAVR) and results in significantly shorter
duration on respirator (1.5 ± 4.3 hrs vs. 17± 49 hrs,
p < 0.001), a substantially yet not significantly shorter ICU
stay (1.3 ± 2.9 days vs. 2.9 ± 7.2 days, p = 0.067) and less
blood transfusions required (1± 2.6 vs. 3.6 ± 6.9) during
the entire postoperative period. Between the two operative
procedures, no significant differences could be found for
the cardiac damage markers troponin T and creatine kin-
ase MB. The significant difference in creatinine is present
pre- and postoperatively whereas its perioperative increase
is similar in both treatment groups.EuroScore 2 and LES
The EuroScore 2 replaced the LES after its presentation
in autumn 2011. Its acquirement is more complex, al-
though more or less the same items are requested. The
refined algorithm leads to lower predicted mortality risks
in most patients, although for some cases, the new algo-
rithm exceeds the risk predicted by LES. The correlation
between the old and the new score is quite poor (Figure 1Table 1 Demographic data of patient collective
TA-TAVI
Number of procedures 76
Sex (% of female pts.) 59.2
Age (yrs) 79 ± 6
30 day mortality 7.9%
Duration ofoperative procedure 80 ± 28 min
Duration on respirator 1.5 ± 4.3 hrs
Days on ICU 1.3 ± 2.9
Blood transfusions During hospital stay 1.0 ± 2.6
postop CK-MB max (µg/l) 27.1 ± 16.4
postop Trop T max (pg/ml) 0.67 ± 0.71
preop max. creatinine (mg/dl) 0.92 ± 0.57
postop max. creatinine (mg/dl) 1.38 ± 0.84
Δ creatinine (mg/dl) 0.46 ± 0.94τ=0.524; τcAVR= 0.510; τTA-TAVI = 0.382 p < 0.001). Of
course the new score will have to be validated in a large
population and new cut off values to triage patients
according to their perioperative risk will have to be
defined. From the data collected in our study, we derived
a maximal Youden’s Index at a cut-off of 2,8%. This cut-
off would have identified 77 pts. as high risk, rightly in-
cluding all 9 of the deceased patients.LES and STS score
Whereas only 10 patients exceed a cut-off value of 10%
mortality as predicted by the STS score, this holds true
for 65 patients if a cut-off value of 20% mortality as pre-
dicted by the LES is taken into account Figure 2. Of
these 65 patients, eight died. On the other hand, the
STS score identified only 2 of the patients that died as
“high risk”. So basically, the surgeons choice is between
a highly specific STS-score (specificity of 0.96 in our
study) that yields a very low sensitivity (0.22) or a very
sensitive (0.89) LES with a fair (0.71) specificity. This is
also reflected in the ROC-curve-analysis. Whereas the
LES reaches an AUC of 0.837 in the entire study popula-
tion (0.869 in cAVR patients and 0.727 in TA-TAVI
patients), STS performance is worse: The AUC in the
entire population only reaches 0.735, with 0.771 for
cAVR patients and 0.561 in TA-TAVI patients. Regard-
ing all deaths, of 9 cases only 2 were correctly marked as
high risk by the STS, whereas only 1 patient was
“missed” by the LES. Additionally, due to the high com-
plexity of the score its calculation was in several cases
incomplete due to missing preoperative data.LES and ACEF
To determine a cut-off value for the ACEF score from
our study population, we observed the ROC curves andcAVR Total p between TA-TAVI
and cAVR
130 206
39.2 46.6
69 ± 11 72 ± 11
2.3% 4.4%
168 ± 42 min
17 ± 49 hrs 0.007
2.9 ± 7.2 0.067
3.6 ± 6.9 0.002
31.5 ± 27.0 0.204
0.64 ± 0.57 0.740
0.72 ± 0.42 0.003
1.05 ± 0.53 0.001
0.35 ± 0.61 0.312
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Figure 1 Direct comparison of EuroScore 2 and LES. The LES shows a wide numeric range. The cut-off value of 20% as recommended by
actual guidelines is marked. Of the deceased patients in both subgroups, all but one exceeded this threshold and were preoperatively identified
as high risk patients. The retrospective evaluation with the EuroScore 2 shows a poor correlation to its predecessor (τ= 0.524; p < 0.01). Only very
few patients exceed a risk score of 10%.
Figure 2 Comparison of the STS-score to the LES in detail and as a mosaic plot. In literature, a STS cut-off value of 10% was recommended
to triage patients as “high risk”. In our population, only very few patients reach this cut off and especially the deceased patients often presented
with a low STS score. In 2 high-risk patients that deceased after the operation, calculation of the STS score was impossible due to missing
information. The mosaic plot is a two dimensional comparison of three variables: The size of the marked area correlates with the number of
patients in the subgroup. At a glance it can be noted that only very few patients exceed an STS score of 10%, that most of these also exceed an
LES of 20% and that no patient with an LES lower 20% and exceeding an STS of 10% deceased.
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−1) for all points on the curve. The index was maximal
for an ACEF score of 1.28 both in the entire population
(YI: 0.644) and in the cAVR subgroup (YI: 0.758). For
TA-TAVI, the index was maximal at an ACEF score of
1.59 (YI: 0.744). In our population, maximal Youden’s
index for the STS score was reached at a score of 4.75%,
for the LES at a score value of 13.05%. The indices at
the recommended cut-offs of 10% for the STS score and
20% for the LES were substantially lower (0.289 and
0.356, respectively), indicating a poor score performance
in our study population. Due to the small population
size, individual calibration of the two complex scores
was statistically not permitted.
Comparison of the ACEF and the LES revealed an al-
most similar performance. Cut down to the ROC-AUC,
ACEF reached 0.874 (LES: 0.837) for the entire popula-
tion. Within the subgroups, ACEF showed an AUC of
0.871 (LES: 0.869) for cAVR patients and an AUC of
0.831 (LES: 0.727) for TA-TAVI patients. Regarding the
entire study population and assuming the self defined
cut-off value of 1.28, ACEF identified 61 patients as
“high risk”, including all 9 deaths as compared to 65
patients identified as “high risk” by the LES including 8
of the 9 deaths (Figure 3).
Discussion
Despite its primary conception for a specific group of
patients, namely those in need of coronary artery bypassFigure 3 Comparison of the calibrated ACEF to the LES. Being the only
used with an individually defined cut off for high-risk patients. The mosaic
ACEF< 1.28 are of almost even size. Whereas the LES missed to mark one p
deceased were equally identified by both risk scores.grafting [16], the LES has been widely adopted to triage
patients, to identify patients at high risk or to choose the
most appropriate surgical approach. It was a well known
fact that the LES overestimated mortality in high risk
patients. Yet the predictive value of a score system can be
viewed in two different ways: The accuracy of prediction
for the individual patient (the discriminative power) or the
scores ability to rightly predict the overall risk of mortality
for all patients (calibration). Following its recent recalibra-
tion and enhancement [9], the Euroscore 2’s capability of
prediction was shown to be improved to its predecessor’s
– yet whether it is still useful to classify patients as high
risk has to be determined. Our study tried to evaluate the
use of EuroScore 2’s discriminative power in the special
case of transapical TAVI, where its predecessor was rou-
tinely used in current recommendations.
As the EuroScore 2, the STS algorithm is based on a
large data set of patients collected in a current time win-
dow and the STS predictive model uses even more cov-
ariates and is therefor quite time-consuming to obtain.
To be of good clinical value, a perfect score system
should be easily acquired and be based on as few vari-
ables as possible. The complexity of the STS and Euro-
Score 2 score renders the scores less attractive for
routine clinical bedside use.
Referring to “the law of Parsimony”, the ACEF Score
Research Group went a step further into simplification in
presenting a score that is only including three major
parameters: renal function, patients’ age and the ejectionscore that can be calibrated on a small population, the ACEF can be
plot shows that the areas for patients with an LES < 20% and an
atient who later died, no patient with an ACEF < 1.28 died. Most
Table 2 Predictive values, specificity and sensitivity of
recommended or self-defined cut-offs
STS LES ACEF Euroscore2
Cut-off 10% 20% 1.28 2.8
PPV 0.20 0.12 0.15 0.17
NPV 0.96 0.99 1.00 1.00
spec. 0.96 0.71 0.74 0.67
sens. 0.22 0.89 1.00 1.00
YI 0.18 0.60 0.74 0.67
F1 0.21 0.22 0.26 0.21
AUC 0.735 0.837 0.874 0.853
For the STS score and the LES, predefined cut offs to identify high risk patients
were taken from current recommendations. The thresholds for the ACEF and
EuroScore2 score were defined from Youden’s Index after recalibration to the
current data set. PPV: positive predictive value; NPV: negative predictive value;
spec.:specificity; sens: sensitivity; F1: f-score; AUC: area under the ROC curve.
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main benefits. A more complex score requires large
populations for calibration, due to the low overall mor-
tality. A score that is defined by only three parameters
can be evaluated in a small population and thus the
ACEF score can be easily calibrated for each clinic, e.g.
using last year’s patient collective for the upcoming year.
Not only allows this a good adaptation to the treated
population, changes will also reflect fluctuations within
the operative statistics that can then be further evaluated.
On one hand, complex comorbidities can hardly be
ignored while they present evident additional risk factors
and are known to increase overall mortality and morbid-
ity. On the other hand, the minimal influence of trad-
itional surgical risk factors on mortality has been shown
for trans-catheter valve replacement [18].
When comparing the probably over-simplistic ACEF
to the detailed EuroScore2 (see also Table 2), both per-
form almost equally in terms of sensitivity, specificity
and predictive values. As comorbidities are growing
within our aging society, a detailed approach might
nevertheless become necessary. To evaluate this fact, lar-
ger populations will provide a deeper insight and are
surely needed to implement new recommendations into
upcoming guidelines. This will have to include distinct-
ive considerations for the different surgical and interven-
tional approaches nowadays available.Limitations of the study
As a single center experience, the presented data might
not be representative. Yet this fact symbolizes the major
problem of most average clinics: Each presents a unique
patient population whose constitution is varied by many
external and internal factors such as clinic size, experi-
ence but also ethnic background and the local health
care system. A general comparability is desirable, yet
clinical decision-making should still be the major causefor the use of risk scores. A weighed approach is there-
for needed and recalibration is a strong benefit of a
score.
Of course it has to be mentioned that the retrospective
design of our study induced a severe bias to the percep-
tion: the performed procedure itself influences the
patients’ mortality, thus, a cAVR patient would have
experienced a different mortality when receiving a TA-
TAVI instead. Additionally, we only included cases of
transapical implantation to our study, upcoming studies
will have to add evidence for the transfemoral approach.
Conclusion
The newly refined EuroScore 2 showed a good correl-
ation within the studied population. For the individual
patient, new cut-offs will have to be defined to triage
patients for TAVI procedure. A drawback for complex
score systems such as EuroScore and STS is the lack of
recalibration to smaller populations as encountered in
even large single centers.
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